ArticleInternational journal of biological sciences2021

Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.

Fang Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.